Evidence map›Paper›PMID 33523233›Full record

Trial reportJournal of the National Cancer Institute2021

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.

Leisha A Emens, Luciana Molinero, Sherene Loi, Hope S Rugo, Andreas Schneeweiss, Véronique Diéras, Hiroji Iwata, Carlos H Barrios, Marina Nechaeva, Anh Nguyen-Duc and 5 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 7 pooled it
20.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 7 syntheses or guidelines pooled it, 286 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. The immunology of human breast cancer.Nature reviews. Immunology · 2026
    Review
  20. Article

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 9 countries.

Leisha A EmensUniversity of Pittsburgh Medical Center, Hillman Cancer Center/Magee Women's Hospital, Pittsburgh, PA, USA.
Luciana MolineroOncology Biomarkers Development, Genentech, Inc, South San Francisco, CA, USA.
Sherene LoiPeter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0001-6137-9171
Hope S RugoDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Andreas SchneeweissNational Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
Véronique DiérasDepartment of Medical Oncology, Institut Curie, Paris, and Centre Eugene Marquis, Rennes, France.
Hiroji IwataBreast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID 0000-0002-0242-4718
Carlos H BarriosCentro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.
Marina NechaevaOncology, Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russia.
Anh Nguyen-DucBiostatistics, Roche, Basel, Switzerland.
Stephen Y ChuiProduct Development, Genentech, Inc, South San Francisco, CA, USA.
Amreen HusainProduct Development, Genentech, Inc, South San Francisco, CA, USA.
Eric P WinerDana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-8819-1723
Sylvia AdamsPerlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.ORCID 0000-0003-4737-1952
Peter SchmidCentre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK.
Aichi Cancer Center · JPArkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser · RUCentre Eugène Marquis · FRDana-Farber Cancer Institute · USGerman Cancer Research Center · DEHospital São Lucas da PUCRS · BRMagee-Womens Hospital · USNew York University · USQueen Mary University of London · GBRoche (Switzerland) · CHThe University of Melbourne · AUUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnderstanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy from the phase 3 IMpassion130 trial, immune biomarkers and BRCA1/2 alterations were evaluated for association with clinical benefit with atezolizumab and nab-paclitaxel (A+nP) vs placebo and nP in unresectable (P+nP) locally advanced or metastatic triple-negative breast cancer.

methodsPatients were randomly assigned 1:1 to nab-paclitaxel 100 mg/m2 (days 1, 8, and 15 of a 28-day cycle) and atezolizumab 840 mg every 2 weeks or placebo until progression or toxicity. Progression-free survival and overall survival were evaluated based on programmed death-ligand 1 (PD-L1) expression on immune cells (IC) and tumor cells, intratumoral CD8, stromal tumor-infiltrating lymphocytes, and BRCA1/2 mutations.

resultsPD-L1 IC+ in either primary or metastatic tumor tissue was linked to progression-free survival and overall survival benefit with A+nP. PD-L1 IC+ low (26.9%; 243 of 902 patients) and high (13.9%; 125 of 902 patients) populations had improved outcomes that were comparable. Intratumoral CD8 and stromal tumor-infiltrating lymphocytes positivity (sTIL+) were associated with PD-L1 IC+ status; improved outcomes were observed with A+nP vs P+nP only in CD8+ and sTIL+ patients who were also PD-L1 IC+. BRCA1/2 mutations (occurring in 14.5% [89 of 612 patients]) were not associated with PD-L1 IC status, and PD-L1 IC+ patients benefited from A+nP regardless of BRCA1/2 mutation status.

conclusionsAlthough A+nP was more efficacious in patients with richer tumor immune microenvironment, clinical benefit was only observed in patients whose tumors were PD-L1 IC+.

Indexed as

Triple Negative Breast NeoplasmsAlbuminsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiomarkersHumansLymphocytes, Tumor-InfiltratingPaclitaxelTumor Microenvironment130-nm albumin-bound paclitaxelAlbuminsAntibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenBiomarkersPaclitaxel

Identifiers

PMID33523233
PMCPMC8328980
OpenAlexW3127482120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.